JP2009527572A - 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子 - Google Patents

免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子 Download PDF

Info

Publication number
JP2009527572A
JP2009527572A JP2008556452A JP2008556452A JP2009527572A JP 2009527572 A JP2009527572 A JP 2009527572A JP 2008556452 A JP2008556452 A JP 2008556452A JP 2008556452 A JP2008556452 A JP 2008556452A JP 2009527572 A JP2009527572 A JP 2009527572A
Authority
JP
Japan
Prior art keywords
composition
antigen
antigens
immunogenic composition
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008556452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009527572A5 (https=
Inventor
デレク ティー． オハーガン，
マンモハン シン，
ジャネット ウェンドルフ，
ジーナ カザズ，
パドマ マルヤラ，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2009527572A publication Critical patent/JP2009527572A/ja
Publication of JP2009527572A5 publication Critical patent/JP2009527572A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2008556452A 2006-02-24 2007-02-24 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子 Withdrawn JP2009527572A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77675706P 2006-02-24 2006-02-24
PCT/US2007/004798 WO2007100699A2 (en) 2006-02-24 2007-02-24 Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013080151A Division JP2013136641A (ja) 2006-02-24 2013-04-08 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子

Publications (2)

Publication Number Publication Date
JP2009527572A true JP2009527572A (ja) 2009-07-30
JP2009527572A5 JP2009527572A5 (https=) 2011-04-14

Family

ID=38326215

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008556452A Withdrawn JP2009527572A (ja) 2006-02-24 2007-02-24 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2013080151A Pending JP2013136641A (ja) 2006-02-24 2013-04-08 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2015047973A Withdrawn JP2015110661A (ja) 2006-02-24 2015-03-11 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2016254929A Pending JP2017057227A (ja) 2006-02-24 2016-12-28 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013080151A Pending JP2013136641A (ja) 2006-02-24 2013-04-08 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2015047973A Withdrawn JP2015110661A (ja) 2006-02-24 2015-03-11 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2016254929A Pending JP2017057227A (ja) 2006-02-24 2016-12-28 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子

Country Status (6)

Country Link
US (1) US8431160B2 (https=)
EP (1) EP1991204A2 (https=)
JP (4) JP2009527572A (https=)
AU (1) AU2007221154A1 (https=)
CA (1) CA2643322C (https=)
WO (1) WO2007100699A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518058A (ja) * 2010-01-24 2013-05-20 ノバルティス アーゲー 放射線照射された生分解性微粒子

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
RU2461390C2 (ru) 2005-01-28 2012-09-20 Галенбио, Инк. Иммунологически активные составы
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2013204315B2 (en) * 2007-10-19 2016-02-18 Glaxosmithkline Biologicals Sa Meningococcal vaccine formulations
BR122016015627A2 (pt) * 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
EP3067048B1 (en) * 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
WO2011009104A1 (en) * 2009-07-16 2011-01-20 The General Hospital Corporation Nucleic acid analysis
EP2282771B1 (en) 2008-04-28 2014-06-25 Novartis AG Method for producing nanoparticles
WO2009146523A1 (en) * 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
US20130029339A1 (en) 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
EP2475988B1 (en) 2009-09-09 2018-11-14 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
EP2530459A4 (en) * 2010-01-27 2017-05-10 National University Corporation Hokkaido University Diffraction microscopy
WO2011117844A2 (en) * 2010-03-26 2011-09-29 Serum Institute Of India Ltd. Method for evaluation of multiple antibodies or multiple antigens in a single sample
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2829819T3 (es) * 2010-08-26 2021-06-02 Toray Industries Composición inmunogénica
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
CA2817111C (en) 2010-11-10 2019-03-05 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US20140105970A1 (en) * 2011-12-01 2014-04-17 Flow Pharma, Inc. Adjuvant and antigen particle formulation
WO2013082503A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9192692B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan stenting paste
US9192574B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan paste wound dressing
US9994605B2 (en) 2014-03-13 2018-06-12 Universitaet Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
CA2996073A1 (en) 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
JP6730744B2 (ja) * 2016-08-04 2020-07-29 ゼノアックリソース株式会社 免疫賦活剤、医薬組成物および飲食品
TWI654993B (zh) * 2016-11-04 2019-04-01 National Health Research Institutes 陽離子型生物可降解性陶瓷聚合物微粒子用以遞送疫苗之用途
US12257294B2 (en) 2018-02-02 2025-03-25 Danmarks Tekniske Universitet Therapeutics for autoimmune disease: synthetic antigens
WO2020252263A1 (en) * 2019-06-12 2020-12-17 Wisconsin Alumni Research Foundation Novel adjuvant for animal and human vaccines
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
CN111728955A (zh) * 2020-06-19 2020-10-02 中山大学 一种用于乙肝治疗的纳米颗粒及其制备方法和治疗性疫苗
US20220160822A1 (en) * 2020-11-23 2022-05-26 Wisconsin Alumni Research Foundation Neutralizing vaccines against human coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540077A (ja) * 1999-03-24 2002-11-26 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
WO2005072088A2 (en) * 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ATE235890T1 (de) 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6514522B2 (en) * 1998-04-08 2003-02-04 Chondros, Inc. Polymer constructs
DE69930642T2 (de) 1998-07-29 2006-12-28 Chiron Corp., Emeryville Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
GB9914412D0 (en) 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
EP1235900B1 (en) 1999-11-19 2006-07-05 Chiron Corporation Microparticle-based transfection and activation of dendritic cells
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
WO2003086454A1 (en) * 2002-04-18 2003-10-23 Akzo Nobel N.V. Antigen-loaded chitosan microparticles for oral vaccination
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
EP1812056B1 (en) 2004-11-15 2013-08-07 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540077A (ja) * 1999-03-24 2002-11-26 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
WO2005072088A2 (en) * 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518058A (ja) * 2010-01-24 2013-05-20 ノバルティス アーゲー 放射線照射された生分解性微粒子

Also Published As

Publication number Publication date
JP2017057227A (ja) 2017-03-23
US20090169636A1 (en) 2009-07-02
EP1991204A2 (en) 2008-11-19
CA2643322A1 (en) 2007-09-07
US8431160B2 (en) 2013-04-30
JP2013136641A (ja) 2013-07-11
WO2007100699A3 (en) 2008-03-13
AU2007221154A1 (en) 2007-09-07
CA2643322C (en) 2015-07-21
JP2015110661A (ja) 2015-06-18
WO2007100699A2 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
JP2017057227A (ja) 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP5806444B2 (ja) 免疫原性組成物で使用するためのナノ粒子
US10485761B2 (en) Irradiated biodegradable polymer microparticles
US9393295B2 (en) Nanoparticles for use in pharmaceutical compositions
US9517263B2 (en) Benzonaphthyridine-containing vaccines
US20110280949A1 (en) Microparticles for use in immunogenic compositions
EP2313085A2 (en) Immunogenic amphipathic peptide compositions
JP2008525423A (ja) 糖結合体ワクチン
AU2013213717A1 (en) Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120914

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140430